Nordicus Partners Corporation Enters Into A Consultancy Agreement With BIO-CONVERT In Denmark

Rhea-AI Summary

Nordicus Partners (OTCQB: NORD), a financial consulting firm, has signed a Consultancy Agreement with Danish biopharmaceutical company BIO-CONVERT. BIO-CONVERT specializes in developing treatments for oral leukoplakia, a potentially cancerous condition. The partnership aims to help BIO-CONVERT establish a U.S. market presence. CEO Henrik Rouf expressed optimism about the collaboration and potential equity investment in BIO-CONVERT. BIO-CONVERT's innovative drug, QR-02, uses advanced technology for precise treatment of oral leukoplakia, potentially preventing oral cancer. The company plans a pilot efficacy study for QR-02.

Positive

• Nordicus Partners signed a new Consultancy Agreement with BIO-CONVERT.
• Potential for Nordicus to take a significant equity stake in BIO-CONVERT.
• BIO-CONVERT is developing an innovative drug, QR-02, for treating oral leukoplakia and preventing oral cancer.
• BIO-CONVERT's drug uses a novel mucoadhesive oral patch technology.
• BIO-CONVERT plans a pilot efficacy study for their new treatment.

Negative

• None.

Beverly Hills, California., June 21, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it entered into a Consultancy Agreement with BIO-CONVERT in Denmark.

BIO-CONVERT ApS (“BIO-CONVERT”) is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of oral leukoplakia, which is a potentially malignant disorder affecting the oral mucosa. Oral leukoplakia is a white patch or plaque that can develop in the oral cavity and cause oral cancer. BIO-CONVERT is developing a new pharmaceutical drug product for the treatment of oral leukoplakia and the prevention of oral cancer formation.

Henrik Rouf, CEO of Nordicus, stated, “We are delighted that BIO-CONVERT chose Nordicus as their exclusive consulting partners to assist with getting established on the U.S. marketplace. As BIO-CONVERT advances in its development of the preferred treatment for oral leukoplakia, Nordicus might further consider taking a significant equity stake in BIO-CONVERT.”

Allan Wehnert, Founder and Board Member of BIO-CONVERT, added “Our innovative therapeutic agent, QR-02, uses a novel drug delivery technology, that enables a more precise, effective and efficient treatment for oral leukoplakia and potentially prevent the formation of oral cancer.

About BIO-CONVERT ApS

BIO-CONVERT ApS, a Denmark-based clinical-stage biopharmaceutical company, is aiming to revolutionize the treatment of oral leukoplakia, by minimizing or removing oral leukoplakia lesions, that further reduces the risk of patients developing oral cancer from it.

BIO-CONVERT has initiated new activities in the field of oral cancer, which involves developing a new drug formulation for the treatment of oral leukoplakia. This is achieved through a proprietary mucoadhesive oral patch formulation that delivers the drug without any systemic absorption. The aim of the treatment is therefore to eliminate the lesions or to reduce the malignant conversion rate of oral leukoplakia to oral cancer. The effect on oral cancer may improve the surgical removal procedure should this be needed for the oral cancer patients.

BIO-CONVERT’s current plan is to conduct a pilot efficacy study in patients with oral leukoplakia. For more information about BIO-CONVERT, please visit: www.bio-convert.com

About Nordicus Partners Corporation

Nordicus Partners Corporation is a Denmark-based financial consulting company, specializing in providing Nordic and U.S. life sciences companies with the best possible conditions to establish themselves on the U.S. market, taking advantage of management’s combined +90 years of experience in the corporate sector, serving in different capacities both domestically and globally. Nordicus’ 95% owned subsidiary, Orocidin A/S, is a clinical-stage biopharmaceutical company which is advancing the next generation of periodontitis therapies. Nordicus’ core competencies lie in assisting Danish as well as other Nordic and international companies in different areas of corporate finance activities, such as: business valuations, growth strategies, attracting capital for businesses and company acquisitions and sales. For more information about Nordicus, please visit: www.nordicuspartners.com

Forward-Looking Statements

The Company believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Terms such as “may,” “might,” “would,” “should,” “could,” “project,” “estimate,” “pro-forma,” “predict,” “potential,” “strategy,” “anticipate,” “attempt,” “develop,” “plan,” “help,” “believe,” “continue,” “intend,” “expect,” “future,” and terms of similar import (including the negative of any of these terms) may identify forward-looking statements. Such forward-looking statements, including but not limited to statements regarding the plans and objectives of management for future operations, are based on management’s current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the accuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, market acceptance of the company’s products and services; competition from existing products or new products that may emerge; the implementation of the company’s business model and strategic plans for its business and our products; estimates of the company’s future revenue, expenses, capital requirements and need for financing; current and future government regulations; and developments relating to the company’s competitors. Readers are cautioned not to place undue reliance on forward-looking statements because of the risks and uncertainties related to them. For further information on such risks and uncertainties, you are encouraged to review the Company’s filings with the Securities and Exchange Commission (“SEC”), including its Current Report on Form 8-K relating to the reverse acquisition and related transactions which was filed with the SEC on March 1, 2023 and its quarterly report on Form 10-Q for the fiscal period ended December 31, 2023. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

For further information contact

Mr. Henrik Rouf
Chief Executive Officer
Phone +1 310 666.0750
Email hr@nordicuspartners.com

FAQ

What recent agreement did Nordicus Partners (NORD) enter into?

Nordicus Partners entered into a Consultancy Agreement with BIO-CONVERT in Denmark.

Who is BIO-CONVERT and what do they specialize in?

BIO-CONVERT is a Danish clinical-stage biopharmaceutical company focused on treating oral leukoplakia and preventing oral cancer.

What is the goal of BIO-CONVERT's drug QR-02?

The goal of QR-02 is to treat oral leukoplakia and prevent the formation of oral cancer through a novel drug delivery technology.

What potential financial move might Nordicus consider regarding BIO-CONVERT?

Nordicus might consider taking a significant equity stake in BIO-CONVERT.

What study is BIO-CONVERT planning for their new treatment?

BIO-CONVERT is planning a pilot efficacy study for their new treatment for oral leukoplakia.